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Background: The aim of this study was to delineate mortality indicators in pneumococcal meningitis with
special emphasis on therapeutic implications.
Methods: This retrospective, multicenter cohort study involved a 15-year period (1998–2012). Culture-
positive cases (n = 306) were included solely from 38 centers.
Results: Fifty-eight patients received ceftriaxone plus vancomycin empirically. The rest were given a
third-generation cephalosporin alone. Overall, 246 (79.1%) isolates were found to be penicillin-
susceptible, 38 (12.2%) strains were penicillin-resistant, and 22 (7.1%) were oxacillin-resistant (without
further minimum inhibitory concentration testing for penicillin). Being a critical case (odds ratio (OR)
7.089, 95% confidence interval (CI) 3.230–15.557) and age over 50 years (OR 3.908, 95% CI 1.820–8.390)
were independent predictors of mortality, while infection with a penicillin-susceptible isolate (OR 0.441,
95% CI 0.195–0.996) was found to be protective. Empirical vancomycin use did not provide significant
benefit (OR 2.159, 95% CI 0.949–4.912).
Conclusions: Ceftriaxone alone is not adequate in the management of pneumococcal meningitis due to
penicillin-resistant pneumococci, which is a major concern worldwide. Although vancomycin showed a
trend towards improving the prognosis of pneumococcal meningitis, significant correlation in statistical
terms could not be established in this study. Thus, further studies are needed for the optimization of
pneumococcal meningitis treatment.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 
Open access under CC BY-NC-SA license.1. Introduction
Pneumococci are the most common agents of acute purulent
meningitis. The disease has a case fatality rate of 17–30%, which is
largely attributed to the complicated pharmacokinetics of the
leptomeninges.1–6 In addition, the worldwide emergence of
penicillin-resistant pneumococcus (PenRP) has complicated the
management of pneumococcal meningitis, eliminating penicillin
from empirical treatment protocols. Ceftriaxone or cefotaxime
with or without vancomycin are currently recommended as the
first-line antibiotics.7–9 However, data on the outcome perfor-
mance of current regimens in this PenRP era are few, and critical
questions regarding whether a vancomycin supplement is ade-
quate or whether other options such as linezolid or daptomycin
should be considered, remain unanswered.
To expand our understanding of the management problems in
pneumococcal meningitis, we undertook a nationwide retrospec-
tive study. This study aimed to investigate independent predictors
of the outcome in pneumococcal meningitis, with special emphasis
on therapeutic implications.
2. Patients and methods
2.1. Study design
This retrospective, multicenter cohort study involved the 15-
year period from January 1998 to December 2012. Patients with
acute bacterial meningitis caused by Streptococcus pneumoniae
were included in the study. A Microsoft Windows-based computer
database was sent out and data were collected from 38
participating centers in Turkey. The Institutional Review Board
of Istanbul Haydarpasa Numune Training and Research Hospital
approved the study protocol.
2.2. Inclusion criteria
Patients with symptoms and signs compatible with meningitis
and with positive cerebrospinal fluid (CSF) cultures for S.pneumoniae, were included in this study. Patients with CSF
pleocytosis and a clinical picture consistent with meningitis were
also included when blood cultures were positive for S. pneumoniae
in the absence of any other probable focus of infection for
pneumococcal disease, in those who were CSF culture-negative.
2.3. Microbiological investigations
All S. pneumoniae isolates were identified by standard
laboratory methods in the clinical microbiology laboratory of
the participating center. Antimicrobial susceptibilities of the
pneumococcal isolates were determined by disk diffusion test,
automated systems, Etests, or microdilution tests, in accordance
with the criteria of the Clinical and Laboratory Standards Institute
(CLSI), or former National Committee for Clinical Laboratory
Standards. The penicillin and ceftriaxone minimum inhibitory
concentration (MIC) values of the isolates were reinterpreted in
accordance with the current guidelines, in which thresholds were
as follows:10,11 penicillin MIC 0.06 mg/l as susceptible and MIC
0.12 mg/l as resistant; ceftriaxone MIC 0.5 mg/l as susceptible,
MIC of 1 mg/l as intermediately resistant, and MIC 2.0 mg/l as
resistant.
In most of our centers, S. pneumoniae was screened by oxacillin
disk test as recommended, and oxacillin-resistant strains were
confirmed by penicillin MIC tests. However, in some of the centers,
oxacillin-resistant isolates were not further tested for MICs.
Therefore, the susceptibility status of isolates was subgrouped
as penicillin susceptible pneumococcus (PenSP), PenRP, or oxacil-
lin-resistant pneumococcus (OxaRP). Since there is a potential
overlap between penicillin- and oxacillin-resistant strains, these
variables were assessed separately in multivariate models.
2.4. Definitions
Glasgow coma scale (GCS) scores of 13 were recorded as mild,
9–12 as moderate, and 8 as poor.12 GCS scores were recorded
separately because patients with severe coma scores might not
have been admitted to the intensive care unit (ICU) unless they
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non-ICU patients with poor GCS scores were classified as ‘critical
cases’.
Underlying diseases were classified according to the McCabe
and Jackson classification scheme.13 Empirical vancomycin treat-
ment was recorded if vancomycin was initiated during the hospital
admission, whereas escalation therapy was defined when vanco-
mycin was added during the course of treatment. De-escalation
therapy was defined as either a switch to a narrower spectrum
agent or the reduction in the number of initial antibiotics,14 which
were penicillin or mostly ceftriaxone alone.
The primary endpoint of this study was 30-day all-cause
mortality.
2.5. Data collection and statistical methods
Data related to demographic characteristics, hospital admission
dates, antibiotic initiation time, and duration of hospital stay were
collected for all patients. For patients followed in the ICUs, the
duration of the ICU stay was also recorded. In univariate analysis,
categorical variables were compared by Pearson’s Chi-square test,
or when necessary by Fisher’s exact test; continuous variables
were compared by Student’s t-test, or by unequal variances t-test
with Welch’s approximation. Significance was inferred at the 0.05
level and was always two-sided.
Variables with a significance value of 0.2 and those recognized
as significant in previous studies were included in the initial
multivariate model. A stepwise backward selection approach was
used in the logistic regression analysis. Variables such as age were
entered and removed from models in categorical or continuous
forms until the best fit was achieved. Confounding, collinearity,
and interaction between terms were tested, and models were
modified accordingly. Model fit was estimated by post-estimation
diagnostic routines such as Hosmer–Lemeshow goodness-of-fit
statistics and classification performances. Adjusted odds ratios
(aOR) were obtained from the final model. Statistical comparisons
were performed using Stata 12 (StataCorp LP, College Station, TX,
USA).
3. Results
A total of 306 patients fulfilling the inclusion criteria were
admitted to the participating centers between 1998 and 2012; 213
were male (69.6%) and 93 were female (30.4%). Pneumococcus was
recovered from the CSF of 301 (98.4%) and from the blood of 71
(22.8%) patients. Blood was the only culture-positive specimen in
five (1.6%) of our patients. Characteristics of the cohort are shown
in Table 1. Briefly, the mean age was 45.3 years (standard deviation
(SD) 18.4, range 14–86 years), and the mean leukocyte and
thrombocyte counts  109/l of blood on admission were
18.4635  8.8142 and 238.0114  101.8171, respectively. On admis-
sion, 259 (84.6%) patients presented with leukocytosis and 10 (3.27%)Table 1
Descriptive characteristics of patients with pneumococcal meningitis (n = 306)
Variable n (%)
Male gender 213 (69.61)
Leukopenia or leukocytosis 269 (87.91)
Head trauma 98 (32.03)
Diabetes mellitus 40 (13.07)
Cerebrovascular event 14 (4.58)
Chronic obstructive lung disease 13 (4.25)
Splenectomy operation 11 (3.59)
Malignancy 8 (2.61)
HIV infection 3 (0.98)
Pregnancy 2 (0.65)
Collagen tissue disorder 1 (0.33)with leukopenia. The GCS score was poor in 72 (23.5%), moderate in
143 (46.7%), and mild in 91 (29.7%) patients. Interestingly, 98 (32%) of
the patients gave a prior history of head trauma. Two patients (0.6%)
had experienced recurrent pneumococcal meningitis.
3.1. Antibiotic treatment
Following the diagnoses of bacterial meningitis on admission,
243 patients received ceftriaxone, five patients received cefotax-
ime, and 58 patients received ceftriaxone plus vancomycin
empirically. The mean time elapsed between hospitalization and
the institution of antibiotics was 3 h (SD 7, range 0.5–72 h) and did
not differ significantly between antibiotic regimens.
Therapy was de-escalated in 28 patients; of these patients, two
(7.1%) died. Therapy was escalated in 28 patients. In 13 of these
patients, vancomycin was added to the therapy following the
isolation of PenRP. Three of these 13 (23.7%) patients died, and six
out of the 10 remaining patients had one of the therapeutic failure
parameters other than penicillin resistance. Neither escalating nor
de-escalating treatment was found to have a significant effect in
terms of the outcome.
3.2. Susceptibility to beta-lactams
All 306 isolates had been screened with oxacillin. A total of 241
(78.7%) isolates were susceptible to oxacillin, while 65 (21.2%)
isolates were found to be resistant. Among oxacillin-resistant
isolates, 43 (14%) were further tested for penicillin MICs and 38
were found to be penicillin-resistant. The remaining 22 oxacillin-
resistant isolates were not tested for the penicillin MIC, hence they
were not confirmed as penicillin-resistant. Eventually, 246 (79.1%)
isolates were assigned as PenSP and 60 isolates were assigned as
OxaRP, of which 38 (12.2%) were PenRP; 22 (7.1%) remained
undetermined in terms of penicillin susceptibility.
3.3. Outcome
A total of 42 out of the 306 patients died of pneumococcal
meningitis within the 30-day follow-up period. The crude
mortality rate (CFR) was 13.7%. Comparison of demographics
and other variables between those who died and those who
survived are shown in Tables 2 and 3. Briefly, age over 50 years,
admission to the ICU, empirical institution of vancomycin, a severe
GCS score, underlying disease, and penicillin resistance of the
isolates were significantly more common among fatal cases.
All these significant variables plus gender, corticosteroid
treatment, and escalation of the treatment, were entered into
the initial model and tested in various forms. We kept gender in the
final model despite this being insignificant. The results of the final
model are presented in Table 4. Accordingly, being a critical case
and age over 50 years were independent predictors of mortality,
while infection with a PenSP isolate was found to be protective. In
this model, PenSP versus the rest (PenRP plus OxaRP) was entered
into the multivariate analysis. In the next step, we dropped
patients infected with OxaRP and analyzed a subgroup of patients
consisting only of patients infected with PenSP and PenRP. In this
subgroup of patients (n = 284) the aORs and corresponding 95%
confidence intervals (CIs) were comparable with the main cohort:
being a critical case (OR 8.34, 95% CI 3.533–19.669) and age over 50
years (OR 4.09, 95% CI 1.813–9.209) were associated with an
adverse outcome, while infection with a PenSP was protective (OR
0.37, 95% CI 0.140–0.960). Controlling corticosteroid treatment did
not change this picture.
Interestingly, in this study the early institution of vancomycin
did not significantly protect patients against an adverse outcome.
In order to further interpret this finding, we performed a subgroup
Table 2
Comparison of risk factors for patients with pneumococcal meningitis who died and those who survived (univariate analysis)a
Died
(n = 42)
Survived
(n = 264)
OR 95% CI p-Value
Male gender 25 (59.52) 188 (71.21) 0.59 0.29–1.25 0.126
Age >50 years 28 (66.67) 95 (35.98) 3.56 1.71–7.66 <0.001
Age >65 years 14 (33.33) 34 (12.88) 3.38 1.48–7.41 <0.001
ICU admission 20 (47.62) 45 (17.05) 4.42 2.09–9.26 0.001
COPD 4 (9.52) 9 (3.41) 2.98 0.64–11.31 0.0001
Diabetes mellitus 9 (21.43) 31 (11.74) 2.05 0.79–4.91 0.068
Prior hospitalizationb 6 (14.29) 21 (7.95) 1.93 0.59–5.37 0.084
Head trauma 7 (16.67) 66 (25) 0.6 0.21–1.46 0.179
Treatment options
Empirical vancomycin 14 (33.33) 44 (16.67) 2.5 1.12–5.37 0.010
Mannitol use 10 (23.81) 80 (30.3) 0.72 0.30–1.59 0.391
Corticosteroid use 22 (52.38) 148 (56.06) 0.86 0.43–1.75 0.656
Prior antibiotic useb 6 (14.29) 44 (16.67) 0.83 0.27–2.16 0.698
Neurosurgery operation 4 (9.52) 30 (11.36) 0.82 0.20–2.53 0.725
Head trauma 9 (21.43) 89 (33.71) 0.54 0.22–1.21 0.113
Glasgow coma scale (GCS) score
13–15 (mild) 5 (11.9) 86 (32.58) <0.0001
9–12 (moderate) 14 (33.33) 129 (48.86)
0–8 (poor) 23 (54.76) 49 (18.56)
McCabe and Jackson (MCJ)
No underlying disease 19 (45.24) 194 (73.48) 0.001
Non-fatal disease 15 (35.71) 49 (18.56)
Ultimately fatal disease 8 (19.05) 21 (7.95)
Susceptibility of pneumococcus
Penicillin-resistant 10 (23.81) 28 (10.61) 0.016
Penicillin-susceptible 27 (64.29) 219 (82.95)
Oxacillin-resistant 5 (11.9) 17 (6.44)
Antibiotic modification
De-escalated 2 (4.76) 26 (9.85) 0.531
Escalated 5 (11.9) 23(8.71)
Unchanged 35 (83.33) 215 (81.44)
Leukopenia 2 (4.76) 8 (3.03) 1.60 0.16–8.41 0.633
Leukocytosis 34 (80.95) 225 (85.23) 0.74 0.31–1.98 0.491
Thrombocytopenia 15 (35.71) 32 (12.12) 4.03 1.78–8.80 <0.001
Thrombocytosis 2 (4.76) 18 (6.82) 0.68 0.07–3.04 1.000
OR, odds ratio; CI, confidence interval; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease.
a Data presented as n (%).
b In the last 3 months.
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vancomycin institution among penicillin-resistant versus penicil-
lin-susceptible isolates is shown in Table 5. In this analysis, among
patients infected with PenRP, two out of nine (22%) died when
vancomycin was instituted, while eight out of 29 (27.6) died
among those who did not receive early vancomycin. On the other
hand, the prognosis of PenSP meningitis was worse when empirical
treatment included vancomycin (n = 17 (23.8%) vs. n = 17 (8.3%);
p = 0.007).
The risk analysis for the development of penicillin resistance is
presented in Table 6. Briefly, the absence of a comorbid disease was
found to be protective against being infected by a PenRP, whereas
having an ultimately fatal comorbid disease significantly increased
the risk.Table 3
Comparison of biochemical parameters for patients with pneumococcal meningitis wh
Died 
Mean (SD) 
WBC,  109/l 18.1814 (8.4599) 
Platelet count,  109/l 200.2286 (11.3273) 
CSF leukocyte count,  106/l 4.1825 (5.215) 
CSF protein (mg/dl) 433.7 (250.30) 
CSF glucose (mg/dl) 14.68 (36.15) 
Blood glucose (mg/dl) 164.7 (81.93) 
CSF/serum glucose 0.08 (0.11) 
SD, standard deviation; WBC, white blood cell count; CSF, cerebrospinal fluid.4. Discussion
This was a nationwide study, and the power of this study lies in
its multicenter nature and high volume of data collection. The
weaknesses of this study include its retrospective design and the
fact that the infecting oxacillin-resistant strains were not further
tested for MIC values in 7% of the patients. However, due to its fatal
nature, data were recorded precisely for pneumococcal meningitis
patients in these Turkish hospitals. Basically, we found several
parameters to be directly related to mortality in patients with
pneumococcal meningitis. Patients of advanced age (over 50 years)
and those with a critical status, including ICU admission or a poor
GCS score, were more likely to die. On the other hand, patients with
meningitis due to susceptible pneumococci more significantlyo died and those who survived (continuous variables)
Survived p-Value
Mean (SD)
18.5084 (8.884) 0.824
244.0223 (98.7814) 0.009
4.014 (4.911) 0.849
322.3 (253.5) 0.013
25.23 (26.91) 0.029
148.6 (66.07) 0.168
0.18 (0.17) <0.001
Table 4
Independent risk factors for death in pneumococcal meningitis (multivariate
logistic regression analysis)
Adjusted OR 95% CI
Male gender 0.480 0.221–1.041
Empirical vancomycin use 2.159 0.949–4.912
Meningitis due to penicillin-
susceptible pneumococcus
0.441 0.195–0.996
Age >50 years 3.908 1.820–8.390
Critical casea 7.089 3.230–15.557
Constant 0.0711 0.024–0.206
OR, odds ratio; CI, confidence interval; ICU, intensive care unit; GCS, Glasgow coma
scale.
a Defined as a case admitted to the ICU or a non-ICU case with a poor GCS score
(8).
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contribute statistically to improving mortality rates. In fact,
patients with a critical status3,15 and of an advanced age3,16 have
been known to die more frequently. However, the antibiotic
resistance issues and empirical antibiotic regimens are known to
impose real challenges on the treating clinician due to their
dynamic natures, and the therapeutic implications may change
rapidly.
There are various risk factors for penicillin nonsusceptibility in
S. pneumoniae isolates, previous antibiotic use being the most
frequent one.17 According to our data, the existence of ultimately
fatal comorbid conditions was linked to the presence of penicillin
resistance. The probable reasons for this association are either
frequent use of antibiotics or repeated attendance in health care
settings for these coexisting disorders. Pneumococcus maintains
penicillin resistance through alterations in penicillin-binding
proteins (PBPs) 1A, 2B, and 2X.18–20 Also, beta-lactam MICs,
including carbapenems, were found to rise with increases in the
number of PBP 1A, 2B, and 2X alterations.21,22 Thus, penicillinTable 6
Risk factors for the development of penicillin resistance among pneumococci
Exposure PenR (n = 38) PenS (n =
n % n 
Gender 26 (68.42) 174 
Age >50 years 15 (39.47) 97 
Underlying diseasea
No underlying disease 20 (52.63) 182 
Non-fatal disease 11 (28.95) 46 
Ultimately fatal disease 7 (18.42) 18 
Diabetes 5 (13.16) 29 
Head trauma 10 (26.32) 83 
Trauma 7 (18.42) 62 
Neurosurgery 5 (13.16) 28 
Splenectomy 2 (5.26) 7 
COPD 2 (5.26) 10 
Antibiotic exposureb 4 (10.53) 41 
Hospitalizationb 2 (5.26) 23 
PenR, penicillin-resistant pneumococcus; PenS, penicillin-susceptible pneumococcus; O
a According to the McCabe and Jackson classification.
b During the 3 months prior to the onset of meningitis.
Table 5
The distribution of empirical vancomycin use with respect to penicillin susceptibility p
Vancomycin Penicillin-resistanta
Died Survived To
Yes 2 (22.2%) 7 (77.8%) 9
No 8 (27.6%) 21 (72.4%) 29
Total 10 (26.3%) 28 (73.7%) 38
a Fisher’s exact test p = 1.000.
b Pearson Chi-square test = 8.5376, p = 0.003.resistance appears to be an indicator of the probability of higher
MICs for other beta-lactam antibiotics among S. pneumoniae
isolates, and accordingly resistance issues appear to be the reason
for the higher mortality in our study. In the study of Gouveia et al.,
various antibiotics were used in the treatment of pneumococcal
meningitis and penicillin resistance seemed to increase mortali-
ty.23 According to the current Infectious Diseases Society of
America (IDSA) guidelines, it is recommended that vancomycin is
given with ceftriaxone or cefotaxime in the empirical treatment of
pneumococcal meningitis until susceptibility results are available.
Subsequently, if the infecting isolate is PenSP, the use of
vancomycin is unnecessary. On the other hand, if the infecting
strain is penicillin- or cephalosporin-resistant, the guidelines
recommend that the patient should continue with the initial
antibiotic combination including vancomycin.7 However, the use
of extended-spectrum cephalosporins alone has been advocated
previously in the literature due to the low resistance profiles in
various parts of the world.9 Accordingly, in a Turkish acute
bacterial meningitis study, the authors commented that vanco-
mycin should be reserved for patients with significant risk factors
for the development of penicillin resistance, and not used on an
empirical basis.8 Many Turkish academics have backed the use of
ceftriaxone alone over the years, due to the less than 1% ceftriaxone
resistance in invasive pneumococci in the country.24,25 Apparently,
this point of view is shared by most Turkish clinicians, and 80% of
the patients in our study received empirical third-generation
cephalosporin alone. In our study, ceftriaxone seemed to fail more
frequently in patients infected with PenRP and OxaRP. More
interestingly, the use of empirical vancomycin seemed not to
compensate significantly for therapeutic failure among pneumo-
coccal meningitis patients, although vancomycin showed a trend
towards improving the prognosis, since the 95% CI was very close
to the statistical threshold (OR 2.159, 95% CI 0.949–4.912).
Conflicting data exist in relatively small studies in the literature. 246) OR 95% CI p-Value
%
(70.73) 0.90 0.41–2.06 0.771
(39.43) 1.00 0.46–2.12 0.996
(73.98) 0.39 0.18–0.84 0.007
(18.70) 1.77 0.74–4.01 0.142
(7.32) 2.86 0.93–7.88 0.025
(11.79) 1.13 0.32–3.26 0.809
(33.74) 0.70 0.29–1.58 0.364
(25.20) 0.67 0.24–1.66 0.364
(11.38) 1.18 0.33–3.40 0.751
(2.85) 1.90 0.18–10.47 0.428
(4.07) 1.31 0.13–6.52 0.733
(16.67) 0.59 0.14–1.79 0.335
(9.35) 0.54 0.06–2.34 0.408
R, odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease.
atterns of Streptococcus pneumoniae
Penicillin-susceptibleb
tal Died Survived Total
 10 (23.8%) 32 (76.2%) 42
 17 (8.3%) 187 (91.7%) 204
 27 (11.0%) 219 (89.0%) 246
H. Erdem et al. / International Journal of Infectious Diseases 19 (2014) 13–1918For example, in a Korean study, in-hospital mortality did not differ
significantly in pneumococcal meningitis when the infecting
agents were either resistant or susceptible to cefotaxime/
ceftriaxone.26 The probable reasons for the inadequacy of
vancomycin as part of the combination regimen may be due to
its low CSF penetration and pneumococcal vancomycin tolerance.
The use of steroids is known to further contribute to reduced
vancomycin penetration into the CSF.27,28 In addition, although
vancomycin-resistant S. pneumoniae has not been identified in the
world, the emergence of vancomycin-tolerant pneumococci is a
matter of great concern and is a relatively new issue that needs to
be clarified on an epidemiological basis.29,30 Consequently, the
hampered efficacy of vancomycin will probably have a potential
impact on the therapeutic strategies in the management of
pneumococcal meningitis. On the other hand, the higher mortality
in the vancomycin arm in PenSP meningitis patients in this study
may highlight the possibility that a third-generation cephalosporin
may not be synergistic or additive with vancomycin; this issue
needs further clarification.
What are the potential strategies to overcome therapeutic
failures in these particular patients? When surveillance data
disclose a higher susceptibility to meropenem, this drug can be
considered as a substitute for ceftriaxone. On the other hand, since
linezolid penetrates the CSF satisfactorily,31 regardless of the use of
steroids, adding this antibiotic to ceftriaxone could be a good
alternative to the vancomycin and ceftriaxone combination.
Nonetheless, linezolid is known to have a bacteriostatic effect,32
which may lead to unsatisfactory outcomes. Initial data for the
efficacy of linezolid and ceftriaxone combination in pneumococcal
meningitis have been published in the literature.33 Several case
series on the use of linezolid in Gram-positive bacterial meningitis
other than pneumococci have also been reported,34–37 as well as
the superiority of linezolid to vancomycin in methicillin-resistant
Staphylococcus aureus meningitis.38 Moreover, resistance to line-
zolid in pneumococci has not been observed in Turkey25,39,40 and is
not a real problem in most parts of the world.41 Thus, linezolid
could be a potential option either alone or in combination,
although this point of view must be supported by well-designed
randomized clinical trials.
Adding rifampin to other antibiotics in the management of
pneumococcal meningitis is another option in cases where
vancomycin has the potential to fail.7 Further studies are also
needed on daptomycin and newer glycopeptides to determine
their place in the management of pneumococcal meningitis.6
There are promising animal pneumococcal meningitis studies
favoring daptomycin over ceftriaxone.42,43 However, the dapto-
mycin penetration rate in the CSF in humans was found to be
around 5–6% through an inflamed blood–brain barrier44 and the
compound was found to be rapidly bactericidal.45 On the other
hand, although daptomycin has been approved at doses of 4 and
6 mg/kg for skin infections and bacteremia, respectively, the
drug has been found to be well tolerated intravenously when
dosed up to 12 mg/kg for 2 weeks.46 There are several case
reports in the literature that show high-dose daptomycin to be
promising as part of a combination regimen in the management
of meningitis.44,47 However, comprehensive data are still lacking
on the use of this drug in central nervous system infections.
Another alternative drug is moxifloxacin, which is recommended
as a substitute to the vancomycin and ceftriaxone combination.
In that context, moxifloxacin can be considered either alone or
as part of the combination regimen, since this antibiotic has
been known to be unaffected by pneumococcal penicillin
resistance.48
In conclusion, our data show that ceftriaxone alone is not
adequate in the management of PenRP meningitis compared to
meningeal infections with susceptible strains. Penicillin resistanceis around 20% according to our data obtained through enrolling
patients treated in the last 15 years. However, penicillin
nonsusceptibility is quite frequent across the world49 and
comprises more than a third of meningeal strains in Turkey
today.50,51 Thus, penicillin resistance is of serious concern to the
treating clinician and this study encourages the decision to
institute a combination regimen on an empirical basis rather than
using third-generation cephalosporins alone in the management of
pneumococcal meningitis. In addition, although a significant
correlation in statistical terms could not be established in this
study, vancomycin tended to improve the prognosis of pneumo-
coccal meningitis. Hence, the data from this study do not strictly
discourage the supplementation of vancomycin when the data
available in the literature are considered. However, new studies
investigating the efficacy of different antibiotic combinations are
needed for the optimization of treatment strategies in the
management of pneumococcal meningitis.
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